INTRODUCTION
Branched-chain a-keto acids (BCKA; a-ketoisovaleric acid, KIV; a-ketoisocaproic acid, KIC; a-keto-,3-methylvaleric acid, KMV)1 can substitute for the corresponding essential branched-chain amino acids (BCAA) (valine, leucine, and isoleucine, respectively) in the keto-,l-methylvaleric acid. diets of both rat and man (1) (2) (3) (4) . The efficiency of branched-chain and other keto acids as dietary substitutes for the corresponding essential amino acids is defined as moles of amino acid required to produce a specific nutritional effect (such as specific rate of growth or specific level of N balance)/moles of corresponding keto acid required to produce the same effect (1) . Efficiency of KIV and KIC in the growing rat varies between 30 and 80% and depends on the growth rate desired (1, 4) . At maximal growth rate, efficiency is 25-30%, so that the minimal daily requirements of KIV and KIC for maximal growth in the immature rat are three to four times greater than those of valine and leucine.
Only two metabolic pathways are available to BCKA: (a) oxidative decarboxylation followed by degradation to CO2 and water for energy purposes (5) ; (b) conversion via transamination into the corresponding BCAA, which can then be incorporated into tissue proteins. In the rat, oxidative decarboxylation is carried out primarily in the liver by a BCKA dehydrogenase complex specific for the three BCKA (6); transamination, however, is largely performed in kidneys and muscle (6, 7) . Theoretically, efficiency of each BCKA is proportional to the ratio, velocity of transamination:velocity of oxidative decarboxylation.
The organ distribution of the BCKA dehydrogenases has so far been studied only in the rat (6) . Recently, BCKA have been proposed as treatment for patients with chronic liver disease who require low protein diets because of hyperammonemia and encephalopathy (3, 8, 9) . If the dehydrogenase is primarily hepatic in man, as it is in the rat, and if the enzyme activity is adversely affected by chronic liver disease, then the efficiency of BCKA as substitutes for BCAA will be higher in cirrhotic than in normal subjects. It will then follow that the amount of BCKA required to replace the corresponding essential amino acid in the diet of cirrhotic patients will be less than in normal individtuals. Also relevant to the treatmlent of cirrhotic patients with exogenous BCKA is the potential neurotoxicity of these substances, as revealed by the fact that excessive levels of endogenous BCKA, resulting from hereditary absence of the BCKA dehydrogenase, cause neurologic disorders in man ("maple syrup urine disease" [10] ).
In view of these considerations, the present study was undertaken to learn the organ distribution of the BCKA dehydrogenases in primate (simian and human) organs, and to measure the specific activity of the enzyme system in normal and cirrhotic human liver.
MIETHODS
Animal tissues. 250-g male Sprague-Dawley rats were fed rat laboratory chow ad lib. They were sacrificed by decapitation and various organs (Table I) were removed for study as described below. In one experiment, the organs were removed and processed within 3 min of death. In another experiment, to determine the effect of a postmortem interval on tissue BCKA dehydrogenase activity, rats were killed and kept at 5°C for 0-12 h before sections of liver, kidney, and muscle were removed and processed.
Eight normal male rhesus monkeys, 3-6 kg in weight, were sacrificed by intravenous pentobarbital. Within 15 min, sections oforgans were removed and processed as below.
Antemortem human tissue. Liver biopsies were obtained at laparotomy from 12 patients whose clinical data are summarized in Table II . Six patients had alcoholic cirrhosis, and six were free of liver disease. Cirrhotic or normal condition of the liver was confirmed by microscope examination of the surgical biopsy. Criteria for cirrhosis were complete bridging between portal areas by fibrous bands and dissection of the lobule with obliteration of central veins. The six cirrhotic patients had all experienced two or more hemorrhages from esophageal varices and were undergoing shunt surgery to relieve portal hypertension. Preoperative clinical evaluation, done within 2 mo before sturgery, gave the results shown in Table II . None of the cirrhotic subjects had experienced encephalopathy. For 1 wk before the operation, patients were given a diet providing each day 2,200-2,500 cal, 80-100 g of protein, 225-270 g of carbohydrate, and 100-120 g of fat. Food was withheld for 12 h before laparotomy.
The six patients with no clinical evidence of hepatic disease, and with normal liver histology, underw%ent laparotomy because of the conditions shown in Table II . Preoperative diet and handling of liver tissue were the same as for cirrhotic patients.
Histologically normal sections of skeletal muscle (rectus abdominis or pectoralis) were obtained from four individuals during laparotomy or radical mastectomy; these subjects were given the same diet preoperatively as specified above.
Postmortem human tissues (Table I) were obtained from 11 individuals at autopsies performed within 4 h after death from acute illnesses (myocardial infarction, trauma, or cerebrovascular accident), less than 2 days in duration. Each tissue sample for which data are presented appeared normal by gross inspection and under light microscopy.
Processing of tissues. A 0.5-1-g section of tissue was excised and chilled to 0°C. Within the next 5 min, (a) 0.1-0.2 g of the tissue was weighed, homogenized for 1 min in 0.9-1.8 ml ice cold 0.25 NI sucrose with a motor-driven Determination of DNA, total N, and collagen. Frozen tissue was homogenized in cold water and the homogenate was lyophilized. 5-10 mg of lyophilized powder was analyzed for DNA according to the method of Martin et al. (14) . 5-10 mg of the powder was digested in concentrated H2S04 and analyzed with 2 ml 6 N HCl in a sealed ampule uinder vacuum at 110°C for 40 h; the hydrolysate was analyzed for hydroxyproline and thereby, collagen (15) .
RESULTS
Preliminary experiments on assay conditions ( Fig. 1) The composition of the complete assay mediuim of WVohlhueter and Harper (6), slightly modified2 is detailed in Tables A and B3 branched-chain dehydrogenase activity of liver and muscle homogenate from rat, monkey, and man was examined. KIC and KIV were both employed as substrates. In general agreement with Wohlhtueter and Harper (6), the activity of the rat enzyme was significantly (P < 0.05) inhibited by these modifications: omission of NAD, coenzyme A, MgCl2, CaCl2, or catalase; replacement of Na+ by K+, K+ by Na+, PO-by Tris, or Cl-by SO=. Oni the other hand, these changes in medium did not influence the rat enzyme activity significantly (P < 0.05): doubling concentration of NAD or thiamine pyrophosphate; addition of lipoate; replacement of Mg++ by Ca+' or Mn+. The branched-chain dehydrogenase activity of liver and muscle from man reacted in a similar way as the rat enzyme to these alterations in meditum composition.
The pH profile for rat, monkey, and human dehydrogenase activity, KIC serving as suibstrate, revealed pH optimutm was 6.8-7.0 in each instance; likewise, temperatture optimtum was between 340 and 40°C for all three species.
The relation of "4CO2 production from KIC by rat and htuman tissue homogenates to (a) concentration of tissue in assay medium and (b) dturation of incubation is shown in Fig. IA min. The reaction velocity for tissu( species increased with keto acid conc 0.5 mM and remained constant betwee (data not shown).
These observations (confirming tl Wendel et al. (16) with human leuko( blasts) established the validity of using tions to assay branched-chain dehydrc in homogenates of monkey and human been used for those of the rat tissues the complete medium described in Table B ;3 tissue concentration, 20 mg/ml; duration of incubation, 20 min; temperature, 370C.
Comparison ofbranched-chain dehydrogenase in rat, monkey, and man Specific and total activities of the BCKA dehydro-T @ genase, with each of the three BCKA as substrate, are shown in Table I . Percent distribution of the body .! -i content was calculated using the formula: organ weight x specific activity/E (organ weight x specific activity)
Rat. Specific activities (U/g wet wt) of the dehydrogenase ranged from: 31 to 34 in liver, 25 to 28 in kidney, 2 to 4 in heart, 2 to 4 in brain and <2 in each of T T the other tissues. However, when percent body dis-+4 tribution was calculated using the above formula, the location of the enzyme activity was 67-76% in liver, 4 ...
12-13% in kidneys, 8-15% in muscle, and <2% in each of the other tissues. Monkey. For the three substrates, the specific activities (U/g wet wt) ranged from: 9 to 14 in liver, 10 to 14 in kidney, 2 to 6 in heart, and <2 in each of the other tissues. The specific activity for muscle was similar to that of rat. The body distribution in the monkey was 48-71% hepatic, 13 (Tables I and II) showed specific entration up to activities similar to those of the 2-4-h postmortem n 0.5 and 8 mM samples. Distribution of body content BCKA dehydrogenase in man was estimated as 60-62% muscular, he findings of 28-32% hepatic, 2% renal, and about 8% in other cytes and fibro-tissues. the same condiIn six cirrhotic livers biopsied at laparotomy, average )genase activity specific activities with KIC, KIV, and KMV as subtissues as have strates were only 20-50% as great as in normal (4, 6) , namely, freshly excised human liver, regardless of whether B. Khatra, R. Chawla wet weight, total N, noncollagen N, or DNA was used as unit of reference (Table II) . The differences were significant at P < 0.05. Average specific activity in cirrhotic liver was 32% of normal. DISCUSSION Specific activities of the rat tissues confirm those of earlier workers (6) . In this species, distribution of the body's content of the enzyme is 70% hepatic, 12% renal, 10% muscular, and 5% other organs. The hepatic-and renal-specific activities being considerably less in monkey and man, a smaller proportion of the body content of the enzyme is located in these organs. In man, only 30% is hepatic, 5% is renal, and the major portion, 60%, is in skeletal muscle.
Another difference between the three species is total body content of enzyme/kilogram of body weight: 1,410-1,610 U/kg in rat, 320-630 U/kg in monkey, and 15-170 U/kg in man.
The present findings have several implications for the use of BCKA in human subjects with nitrogen accumulation diseases: (a) the efficiency of the BCKA as substitutes for the BCAA is theoretically a function of the ratio, rate of decarboxylation:rate of transamination. In the rat, efficienvcy of KIN' and KIC varies with the growth rate desired, but at maximal growth, is only about 30%. Sincee the human body content of branched-chain dehydrogenase, expressed as units/kilogram lean body mass, is only 1/30th as great as in the rat, the nutritional efficiency of BCKA in man may be considerably greater than 30%. The picture will be incomplete, however, until the specific activities of branched-chain aminotransferases in human tissues are determined. (b) The nutritional efficiency of BCKA in cirrhotic patients will probably be greater than in normal subjects for the following reasons. Assume that branched-chain aminotransferase is largely extrahepatic in man, as in the rat. Orallyingested BCKA are delivered in normal subjects via the portal vein to the liver; only those molectules which escape decarboxylation by the hepatic brainchedchain dehydrogenase can reach the extrahepatic aminotransferases. Therefore, the decline in the hepatic enzyme's activity caused by cirrhosis (Table II) may increase the proportion of ingested BCKA which is available for transamination. Furthermore, the rate of decarboxylation of ingested BCKA in the liver will be determined not only by the enzyme's specific activity, but also by the mass of the liver and the rate of portal blood flow. All three factors will be reduced in advanced cirrhosis. In the present series of cirrhotics, moreover, cases with advanced hepatocellular failure were excluded by the criteria for shunt surgery (17) , as indicated by the only moderate accumtilation of collagen and DNA (Table II) compared to autopsy specimens of cirrhotic liver (18, 19) , by the absence of encephalopathy, and by the limited degree of inflammation and fat infiltration in the liver (Tables A  and B) .3 Thus we can expect an even greater than 70% reduction in specific activity of hepatic branichedchain dehydrogenase to occur in cirrhotic patients with more advanced disease than the present cases. Finally, natural or surgical portasystemic shunting in cirrhotic patients will further reduce the proportion of ingested BCKA which is catabolized by oxidative decarboxylation in the liver and increase the proportion available for transamination to BCAA in extrahepatic tissues. (c) Intravenously administered BCKA, however, can be expected to possess similar efficiency in cirrhotic and normal subjects, because the body content of BCKA dehydrogenase would be reduced only 20% by even total loss of the hepatic dehydrogenase. (d) Since the human kidneys contain <5% of the body's branchedchain dehydrogenase, advanced renal disease will have negligible effect on the metabolic degradation of BCKA. The normal human kidney may, however, contribute more imnportaintly to transam inationi of BCKA; if so, the nutritional efficiency of BCKA in uremics couild be impaired.
It must be emphasized that the discussion above concerning the probable effects of hepatic and renal disease on the nutritional efficiency of BCKA administered by the oral and intravenous routes is not (Ituantitative and attempts only to predict the direction of the anticipated changes. Rates of decarboxvlation and transamination of BCKA in vivo will depend not only on enzymatic-specific activities as measured in vitro, but also on the in vivo concentrations of reactants in the enzymatic process, and on the in vivo concentrations of BCKA at the surfaces of the involved enzymes. Monitoring of blood levels of BCKA dturing tieatment of patienits will be necessary in order to (qtiantify the effect of cirrhosis on the metabolismii of these compounds.
